Translate to...

Biocon#39;s partner Equillium plans Itolizumab#39;s global clinical trial for COVID-19

Biocon#39;s partner Equillium plans Itolizumab#39;s global clinical trial for COVID-19

Biocon#39;s partner Equillium plans Itolizumab#39;s global clinical trial for COVID-19 Biocon has out-licensed Itolizumab to US-based biotech firm Equillium in 2017 for development in the US and Canada. Equillium has been awarded ‘fast track’ and ‘orphan drug’ designations for the molecule in both prevention and treatment of graft-versus-host disease by the USFDA.